U.S. Allergy Immunotherapy Market Size, Share, Analysis, By Type (Subcutaneous Immunotherapy and Sublingual Immunotherapy), By Application (Allergic Rhinitis, Allergic Asthma, and Others), By Distribution Channel (Hospital Pharmacies and Retail Pharmacies & Online Pharmacies), and Country Forecast, 2023-2030

The U.S. allergy immunotherapy market size was worth USD 254.0 million in 2023 and is projected to grow at a CAGR of 10.4% during the forecast period. 

Allergy immunotherapy or allergen desensitization is a repeated administration of specific allergens into an individual suffering from immunoglobulin E (IgE)-mediated conditions. These therapies are administered in order to protect against the inflammatory reactions and allergic symptoms caused due to exposure to allergens such as house mites, pollens, insects, and others.

The U.S. is witnessing a significant rise in the incidence of different types of allergies every year.  The increasing burden of allergies in the country raises the demand for effective treatments such as immunotherapy. According to the Centers for Disease Control and Prevention 2023 data, around 25.7% of the adult population in the country suffered from seasonal allergies in 2021.

The rising awareness among the population to improve health and manage allergies and approval of products by the regulatory bodies, among others, are a few factors driving the adoption of allergy immunotherapy products in the country.

The market witnessed a decline during the COVID-19 pandemic due to fewer patient visits to the clinics. Also, increased usage of masks and reduction in outdoor activities during the pandemic lowered the exposure to allergens, thereby reducing patient numbers.

U.S. Allergy Immunotherapy Market Trends

Shifting Focus to Promote the Adoption of Sublingual (SLIT) Immunotherapy Tablets for Allergies

SLIT tablets have various benefits over SCIT, such as ease of administration, safety, and fewer systemic allergic reactions. This makes these products a popular therapy among patients and healthcare professionals. The doctors in the country are encouraging the usage of SLIT products.

• For instance, according to a survey published by the American College of Allergy, Asthma, and Immunology, about 73.0% of physicians prescribed SLIT (under-the-tongue) allergy tablets for managing allergies.

The increase in product approvals by the regulatory bodies is also supporting the SLIT tablets market growth.

U.S. Allergy Immunotherapy Market Growth Factors

Increasing Prevalence of Allergies to Propel the Demand for Immunotherapy Drugs

The rising cases of allergies in the country are one of the predominant factors raising the demand for allergy immunotherapy drugs.

• According to the Asthma and Allergy Foundation of America, in 2021, an estimated 81.0 million people in the U.S. were diagnosed with hay fever.

Furthermore, increasing government initiatives to raise awareness regarding the effective management of allergic symptoms is augmenting the adoption of these drugs among patients. Moreover, the launch of new products by industry players to meet the surging demand is projected to contribute to the U.S. allergy immunotherapy market growth.

In 2021, the prevalence of allergic rhinitis and allergic asthma cases in the U.S. was around 81.0 million and 26.0 million, respectively.

RESTRAINING FACTORS

Lack of Proper Adherence to Medications and the Availability of Alternatives to Impede Market Expansion

A few disadvantages of immunotherapy products, such as low efficiency, inconvenience caused to the patients, and the high cost of the treatment regimen, compared to other alternative drugs available, are likely to hinder the market growth in the U.S. Furthermore, the complications associated with immunotherapy, such as reactions at the injection site, anaphylaxis, and others, limit their adoption.

• For instance, as per an NCBI article published in 2022, the adverse effects associated with SCIT and SLIT therapy and the inconvenience caused by SCIT products is the predominant reason for the discontinuation of these therapies among patients.

The availability of cost-effective alternative products, such as antihistamine nasal sprays, and leukotriene receptor antagonists, among others, in the U.S. market is likely to restrict market growth. For instance, the cost of antihistamine nasal spray in the U.S. is around USD 13 – 20. However, the average price for an allergy shot is about USD 100 per dose.

Moreover, alternative products are easily available as OTC products. On the other hand, immunotherapy products require a doctor’s prescription for purchase.

U.S. Allergy Immunotherapy Market Segmentation Analysis

By Type Analysis

Based on type, the market is fragmented into subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT).

The subcutaneous immunotherapy segment held the largest share in 2022. SCIT is the gold standard treatment for allergies with higher efficiency when compared to SLIT products. Moreover, an increase in the number of product launches is contributing to the market growth in the U.S.

• According to an NCBI article published in 2021, subcutaneous immunotherapy (SCIT) is 80% effective for treating allergies compared to SLIT.

The sublingual immunotherapy is anticipated to exhibit the fastest growth during the forecast period. The shifting preference toward sublingual immunotherapy (SLIT) products among patients and healthcare professionals is anticipated to bolster market growth in the upcoming years. This can be attributed to their fewer complications and easy and convenient use.

By Application Analysis

Based on application, the market is subdivided into allergic asthma, allergic rhinitis, and others.

The allergic rhinitis segment held the largest U.S. allergy immunotherapy market share in 2022. The rising prevalence of allergic rhinitis in the country and the launch of new products indicated for allergic rhinitis are some factors propelling the market growth.

• For instance, in January 2023, the U.S. FDA approved Odactra, a sublingual immunotherapy for treating house dust mite-induced allergic rhinitis.

Allergic asthma is projected to grow at the fastest CAGR during the forecast period. The rising focus of the players to develop immunotherapy for asthma coupled with the growing prevalence of the condition in the country are a few factors contributing to the growth of the market in the U.S.

By Distribution Channel Analysis

Based on distribution channel, the market is segmented into hospital pharmacies and retail pharmacies & online pharmacies.

The retail pharmacies & online pharmacies accounted for the largest U.S. allergy immunotherapy market share in 2022. The growing number of online & retail pharmacies in the country, along with shifting patient preference to buy medicine from online pharmacies due to convenience, special discounts, and others, is increasing the revenue generation from the segment.

• For instance, in November 2020, Amazon launched an online pharmacy in the U.S. to deliver prescription drugs. The pharmacy would provide discounts, price comparisons of various drugs, and others to the customers.

Such benefits are set to favor the online & retail pharmacies segment growth over the forecast period.

The hospital pharmacies witnessed considerable growth in the forthcoming years. The increasing number of hospital admissions related to allergies and the growing patient population, among others, are contributing to the segment’s growth.

List of key Companies in U.S. Allergy Immunotherapy Market

Considering the competitive landscape, the market depicts the presence of established companies. ALK Abello dominated the U.S. market in 2022. Some other leading players operating in the U.S. allergy immunotherapy market are Stallergenes Greer, Allergy Therapeutics, HollisterStier Allergy, and others. The various strategic initiatives adopted by these companies, such as product launches, investment in research and development, seeking regulatory approval for their products, expansion of manufacturing facilities, and others, are the key factors bolstering the market share of these companies.

• For instance, in November 2018, Stallergenes Greer received U.S. FDA approval for Oralair SLIT tablet indicated to treat grass pollen allergy among pediatrics.

LIST OF KEY COMPANIES PROFILED:

• ALK (Denmark)


• Stallergenes Greer (Switzerland)


• Allergy Therapeutics (U.K.)


• HollisterStier Allergy (U.S.)


• Dermapharm Holding SE (Germany)


• HAL Allergy B.V. (Netherlands)

KEY INDUSTRY DEVELOPMENTS:

June 2023: ALK announced the phase 3 clinical trial positive results of its sublingual allergy immunotherapy tablet for treating house dust mite (HDM)-induced allergic rhinitis in pediatric patients.

October 2021: Stallergenes Greer partnered with Aptar Pharma to develop novel connected devices for the delivery of allergy immunotherapy drugs.

May 2021: ALK partnered with the New York Government through a digital venture collaboration to persuade more allergy patients in the U.S. to buy SLIT tablets from ALK.

REPORT COVERAGE

The market research report provides a detailed analysis of the market. It focuses on key aspects such as an overview of the technological advancements, the prevalence of allergic rhinitis, allergic asthma in the U.S., and pricing analysis. In addition, it includes pipeline analysis, new product launches, key industry developments such as mergers, partnerships, and acquisitions and the impact of COVID-19 on the market. Besides this, the report also offers insights into the market trends and highlights key industry dynamics. In addition to the aforementioned factors, it encompasses several factors that have contributed to the growth of the market over recent years.

Report Scope & Segmentation